Evidence map›Paper›PMID 21836103›Full record

Trial reportDiabetes care2011

Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial.

Jessica L Unick, Daniel Beavers, John M Jakicic, Abbas E Kitabchi, William C Knowler, Thomas A Wadden, Rena R Wing, Look AHEAD Research Group

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 9 pooled it
24.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 9 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Jessica L UnickWeight Control and Diabetes Research Center, The Miriam Hospital and Brown Medical School, Providence, Rhode Island, USA. junick@lifespan.org
Daniel Beavers
John M Jakicic
Abbas E Kitabchi
William C Knowler
Thomas A Wadden
Rena R Wing
Look AHEAD Research Group
Miriam Hospital · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Tennessee Health Science Center · USWake Forest University · US

Funding

Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI ALBERT, RICHARD K · 1985 to 2008
$52.6M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HALL, JANET E · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCAMILLA, MICHAEL A · 1985 to 2008
$23.1M
SHOW PROJECTU01DK057154 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1999 to 2020
$23.1M
Look AHEAD: Action for Health DiabetesU01DK057178 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1999 to 2020
$21.2M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI SEO, PHILIP · 1986 to 2007
$20.2M
The Look AHEAD Continuation: Action for Health in DiabetesU01DK057078 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, KAREN C · 1999 to 2020
$20.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057135 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI WADDEN, THOMAS A. · 1999 to 2020
$20.0M
Intramural NIH HHSNCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01RR000056 44NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01RR0021140NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR01066NCRR NIH HHS M01RR01346NCRR NIH HHS M01RR02719NIDDK NIH HHS DK-046204NIDDK NIH HHS DK-56990NIDDK NIH HHS DK-56992NIDDK NIH HHS DK-57002NIDDK NIH HHS DK-57008NIDDK NIH HHS DK-57078NIDDK NIH HHS DK-57131NIDDK NIH HHS DK-57135NIDDK NIH HHS DK-57136NIDDK NIH HHS DK-57149NIDDK NIH HHS DK-57151NIDDK NIH HHS DK-57154NIDDK NIH HHS DK-57171NIDDK NIH HHS DK-57177NIDDK NIH HHS DK-57178NIDDK NIH HHS DK-57182NIDDK NIH HHS DK-57219NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK079637NIDDK NIH HHS P30 DK48520NIDDK NIH HHS P60 DK079637NIDDK NIH HHS P60DK079637NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219
6 · The paper itself

Abstract

objectiveRates of severe obesity (BMI ≥40 kg/m(2)) are on the rise, and effective treatment options are needed. We examined the effect of an intensive lifestyle intervention (ILI) on weight loss, cardiovascular disease (CVD) risk, and program adherence in participants with type 2 diabetes who were severely obese compared with overweight (BMI 25 to <30 kg/m(2)), class I (BMI 30 to <35 kg/m(2)), and class II (BMI 35 to <40 kg/m(2)) obese participants. RESEARCH DESIGN AND

methodsParticipants in the Action for Health in Diabetes (Look AHEAD) trial were randomly assigned to ILI or diabetes support and education (DSE). DSE participants received a less intense educational intervention, whereas ILI participants received an intensive behavioral treatment to increase physical activity (PA) and reduce caloric intake. This article focuses on the 2,503 ILI participants (age 58.6 ± 6.8 years).

resultsAt 1 year, severely obese participants in the ILI group lost -9.04 ± 7.6% of initial body weight, which was significantly greater (P < 0.05) than ILI participants who were overweight (-7.43 ± 5.6%) and comparable to class I (-8.72 ± 6.4%) and class II obese (-8.64 ± 7.4%) participants. All BMI groups had comparable improvements in fitness, PA, LDL cholesterol, triglycerides, blood pressure, fasting glucose, and HbA(1c) at 1 year. ILI treatment session attendance was excellent and did not differ among weight categories (severe obese 80% vs. others 83%; P = 0.43).

conclusionsSeverely obese participants in the ILI group had similar adherence, percentage of weight loss, and improvement in CVD risk compared with less obese participants. Behavioral weight loss programs should be considered an effective option for this population.

Indexed as

Life StyleAgedBehavior TherapyDiabetes Mellitus, Type 2Energy IntakeFemaleHumansMaleMiddle AgedMotor ActivityObesityPatient Education as TopicTreatment OutcomeWeight Reduction Programs

Identifiers

PMID21836103
PMCPMC3177753
OpenAlexW2120919105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.